PECAM1 and neoplasm: Showing that the anti-angiogenic and consequently anti-tumor role of DAHP is time-dependent, Pickert et al. showed that the administration of DAHP (100 mg/kg) twice daily orally immediately after tumor cells inoculation reduced the formation of blood vessels as indicated by decreased CD31 and αvβ3 integrin staining [62].